210 related articles for article (PubMed ID: 35380158)
1. Molecular Imaging of Neuroendocrine Neoplasms.
Refardt J; Hofland J; Wild D; Christ E
J Clin Endocrinol Metab; 2022 Jun; 107(7):e2662-e2670. PubMed ID: 35380158
[TBL] [Abstract][Full Text] [Related]
2. Molecular Imaging in neuroendocrine neoplasias.
Christ E; Wild D; Refardt J
Presse Med; 2022 Jun; 51(2):104115. PubMed ID: 35131317
[TBL] [Abstract][Full Text] [Related]
3. Theranostics in neuroendocrine tumors: an overview of current approaches and future challenges.
Refardt J; Hofland J; Kwadwo A; Nicolas GP; Rottenburger C; Fani M; Wild D; Christ E
Rev Endocr Metab Disord; 2021 Sep; 22(3):581-594. PubMed ID: 32495250
[TBL] [Abstract][Full Text] [Related]
4. New Directions in Imaging Neuroendocrine Neoplasms.
Refardt J; Hofland J; Wild D; Christ E
Curr Oncol Rep; 2021 Nov; 23(12):143. PubMed ID: 34735669
[TBL] [Abstract][Full Text] [Related]
5. Current Status of Radiopharmaceuticals for the Theranostics of Neuroendocrine Neoplasms.
Fani M; Peitl PK; Velikyan I
Pharmaceuticals (Basel); 2017 Mar; 10(1):. PubMed ID: 28295000
[No Abstract] [Full Text] [Related]
6. [
Giovannini E; Giovacchini G; Borsò E; Lazzeri P; Riondato M; Leoncini R; Duce V; Ciarmiello A
Curr Radiopharm; 2019; 12(1):11-22. PubMed ID: 30539709
[TBL] [Abstract][Full Text] [Related]
7. NEN - the role of somatostatin receptor scintigraphy in clinical setting.
Opalińska M; Hubalewska-Dydejczyk A; Sowa-Staszczak A; Stefańska A
Nucl Med Rev Cent East Eur; 2016; 19(2):118-25. PubMed ID: 27479789
[TBL] [Abstract][Full Text] [Related]
8. The Value of Somatostatin Receptor Scintigraphy (SRS) in Patients with NETG1/G2 Pancreatic Neuroendocrine Neoplasms (p-NENs).
Kolasińska-Ćwikła AD; Konsek SJ; Buscombe JR; Maciejkiewicz K; Cichocki A; Roszkowska-Purska K; Sawicki Ł; Tenderenda M; Cwikla JB
Nucl Med Rev Cent East Eur; 2019; 22(1):1-7. PubMed ID: 30276787
[TBL] [Abstract][Full Text] [Related]
9. Does somatostatin or gastric inhibitory peptide receptor expression correlate with tumor grade and stage in gut neuroendocrine tumors?
Körner M; Waser B; Reubi JC
Neuroendocrinology; 2015; 101(1):45-57. PubMed ID: 25591947
[TBL] [Abstract][Full Text] [Related]
10. Glucose-dependent insulinotropic polypeptide receptors in most gastroenteropancreatic and bronchial neuroendocrine tumors.
Waser B; Rehmann R; Sanchez C; Fourmy D; Reubi JC
J Clin Endocrinol Metab; 2012 Feb; 97(2):482-8. PubMed ID: 22112810
[TBL] [Abstract][Full Text] [Related]
11. Molecular imaging for neuroendocrine tumours.
Antwi K; Nicolas G; Wild D; Christ E
Swiss Med Wkly; 2019 Feb; 149():w20017. PubMed ID: 30852831
[TBL] [Abstract][Full Text] [Related]
12. Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients.
Zhang J; Kulkarni HR; Singh A; Niepsch K; Müller D; Baum RP
J Nucl Med; 2019 Mar; 60(3):377-385. PubMed ID: 30115686
[TBL] [Abstract][Full Text] [Related]
13. Role of Somatostatin Receptor in Pancreatic Neuroendocrine Tumor Development, Diagnosis, and Therapy.
Hu Y; Ye Z; Wang F; Qin Y; Xu X; Yu X; Ji S
Front Endocrinol (Lausanne); 2021; 12():679000. PubMed ID: 34093445
[TBL] [Abstract][Full Text] [Related]
14. Somatostatin receptors: from signaling to clinical practice.
Theodoropoulou M; Stalla GK
Front Neuroendocrinol; 2013 Aug; 34(3):228-52. PubMed ID: 23872332
[TBL] [Abstract][Full Text] [Related]
15. Tumor imaging and therapy using radiolabeled somatostatin analogues.
de Jong M; Breeman WA; Kwekkeboom DJ; Valkema R; Krenning EP
Acc Chem Res; 2009 Jul; 42(7):873-80. PubMed ID: 19445476
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic applications of radiolabeled peptides in nuclear endocrinology.
Behr TM; Béhé M; Becker W
Q J Nucl Med; 1999 Sep; 43(3):268-80. PubMed ID: 10568142
[TBL] [Abstract][Full Text] [Related]
17. Imaging tumors with peptide-based radioligands.
Behr TM; Gotthardt M; Barth A; Béhé M
Q J Nucl Med; 2001 Jun; 45(2):189-200. PubMed ID: 11476170
[TBL] [Abstract][Full Text] [Related]
18. Evolution in the treatment of gastroenteropancreatic-neuroendocrine neoplasms, focus on systemic therapeutic options: a systematic review.
Pusceddu S; De Braud F; Festinese F; Bregant C; Lorenzoni A; Maccauro M; Milione M; Concas L; Formisano B; Leuzzi L; Mazzaferro V; Buzzoni R
Future Oncol; 2015; 11(13):1947-59. PubMed ID: 26161929
[TBL] [Abstract][Full Text] [Related]
19. [The relevance of PET/CT for the surgical management of neuroendocrine neoplasms].
Hommann M; Kaemmerer D; Hörsch D; Kulkarni HR; Robiller F; Baum RP
Chirurg; 2014 Jun; 85(6):500-4. PubMed ID: 24844432
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of somatostatin receptor type 2 in neuroendocrine tumors for improved Ga68-DOTATATE imaging and treatment.
Guenter R; Aweda T; Carmona Matos DM; Jang S; Whitt J; Cheng YQ; Liu XM; Chen H; Lapi SE; Jaskula-Sztul R
Surgery; 2020 Jan; 167(1):189-196. PubMed ID: 31629542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]